Key result
Continuous intravenous infusion of adriamycin at /sq m/day demonstrated clinical activity in various cancers with substantially reduced toxicity compared to standard bolus schedules.
Why the study?
Does a continuous intravenous infusion of adriamycin reduce toxicity while maintaining clinical activity in patients with cancer?
Does a continuous intravenous infusion of adriamycin reduce toxicity while maintaining clinical activity in patients with cancer?
A 30-day continuous infusion of adriamycin at 3 mg/m2/day reduces toxicity, including potential cardiotoxicity, while maintaining clinical antineoplastic activity.
Answers are grounded in this paper and cite their sources.
Supports evaluation of continuous adriamycin infusion in prospective trials; leaves open confirmation of reduced cardiotoxicity versus bolus.
Eighteen patients received a continuous intravenous infusion of adriamycin for 14-60 days in a phase I study in which the dose rates were escalated from 2 mg/sq m/day to 5 mg/sq m/day to establish the optimal dose to be delivered over a 30-day period. The drug was delivered via a tunneled subclavian catheter by a portable infusion pump (Cormed model ML-6) primed to provide a volume of diluted drug of 10 cc/day. Leukopenia and stomatitis were observed at 4 mg/sq m/day doses or greater in 50% of courses. At doses less than 4 mg/sq m/day, only 3/17 courses (18%) were associated with stomatitis. Partial alopecia developed in all patients, but less than 50% of scalp hair was affected. The cumulative dose of continuous infusion adriamycin at 30 days is comparable to the dose delivered by standard bolus intermittent schedules (60-90 mg/sq m g 21 days), but the adverse drug effects are eliminated or substantially reduced. Cardiac toxicity was assessed in selected patients treated to 450 mg/sq m or greater by cardiac biopsy and/or gated pool studies. No histopathologic lesions were noted in 3 patients receiving 450 mg/sq m or greater. The recommended daily dose rate of adriamycin in this protracted infusion regimen is 3 mg/sq m/day. The phase II study of this schedule and dose rate in 38 additional patients (a total of 52 evaluable patients) demonstrated objective responses in 1/9 soft tissue sarcoma, 1/3 mesothelioma, 1/3 hepatoma, and 2/13 breast cancer. Phase III studies of the protracted continuous infusion schedule for adriamycin are indicated in that clinical activity is demonstrated at a substantial reduction in toxicity. Pharmacologic studies expanding the existing data base are also necessary.
No takes yet. Share an insight, caveat, or question.
Lokich et al. (1983) studied Cancer (soft tissue sarcoma, mesothelioma, hepatoma, breast cancer) (n=56). Continuous intravenous infusion of adriamycin was evaluated on Optimal dose, toxicity, and objective response. Continuous intravenous infusion of adriamycin at /sq m/day demonstrated clinical activity in various cancers with substantially reduced toxicity compared to standard bolus schedules.
Synapse has enriched 10 related papers. Consider them for comparative context: